ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Oruka Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$74.48+2.55 (+3.55%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$47.00 (+171.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$132.89M
- Free cash flow
- -$101.15M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$155.08M
Net income
-$132.89M
EPS, diluted
–
Free cash flow
-$101.15M
Reported periodTrailing twelve months